Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Diabetic Retinopathy Market Size, Value And Growth Trends Through 2030

Experiencing robust expansion recently, the diabetic retinopathy market is projected to climb from $9.26 billion in 2025 to $9.97 billion by 2026, demonstrating a compound annual growth rate of 7.6%. Factors contributing to this historical momentum include a surge in diabetes diagnoses, delays in identifying retinal damage, restricted access to screening services, escalating instances of visual impairment, and a reliance on institutional eye care facilities.

The market for diabetic retinopathy is projected for substantial expansion over the coming years, anticipated to reach $13.54 billion by 2030, driven by a compound annual growth rate of 8.0%. This anticipated upswing is fueled by several key factors, including the increasing prevalence of AI-supported screening technologies, the proliferation of ophthalmology practices, a greater uptake of anti-VEGF therapies, a heightened emphasis on preventative eye health strategies, and a growing elderly population diagnosed with diabetes. Key market developments during this period are expected to involve a more widespread implementation of retinal screening initiatives, augmented utilization of anti-VEGF treatments, enhanced capabilities in early detection and ongoing monitoring, the increasing incorporation of AI in retinal imaging analysis, and a sustained focus on preserving vision.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12187&type=smp

Diabetic Retinopathy Market Opportunity Drivers: What Is Creating New Revenue Potential?

The escalating incidence of diabetes is poised to be a significant catalyst for the expansion of the diabetic retinopathy market. Diabetes, characterized by persistently elevated blood glucose, stems from factors such as excess weight, obesity, genetic predispositions, and a lack of physical activity. Individuals with diabetes experience hyperglycemia, which poses a risk to the retina, the light-sensitive tissue responsible for transmitting visual information to the brain via the optic nerve. Illustrating this trend, data from the Office for Health Improvement and Disparities in the UK, released in March 2024, indicated a substantial improvement in care for diabetic patients. Specifically, from March 2022 to March 2023, the proportion of individuals undergoing all eight recommended care procedures saw a 22% increase for type 1 diabetes and a 21% rise for type 2 diabetes. Furthermore, the National Diabetes Audit reported a record high of 37.9% of individuals achieving target HbA1c levels, underscoring the growing awareness and management of diabetes, which in turn fuels the demand within the diabetic retinopathy market.

Diabetic Retinopathy Market Segments: Where Are The Largest Growth Opportunities?

The diabetic retinopathy market covered in this report is segmented –

1) By Type: Proliferative Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy

2) By Treatment: Anti-VEGF Drugs, Intraocular Steroid Injection, Laser Photocoagulation, Vitreoretinal Surgery

3) By End-User: Hospitals, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Proliferative Diabetic Retinopathy (PDR): Neovascularization, Vitreous Hemorrhage, Tractional Retinal Detachment

2) By Non-Proliferative Diabetic Retinopathy (NPDR): Mild NPDR, Moderate NPDR, Severe NPDR

Diabetic Retinopathy Market Innovation Trends Driving Future Development

Leading entities within the diabetic retinopathy sector are actively pursuing alliances to enhance their market standing and financial gains. These collaborations in the diabetic retinopathy field involve joint initiatives among diverse stakeholders, including medical practitioners, scientific investigators, drug manufacturers, and patient advocacy organizations, all working together to overcome the obstacles presented by diabetic retinopathy. As an illustration, in October of 2023, AEYE Health, an American company specializing in AI-driven diagnostic tools for retinal imagery, joined forces with Topcon Screen, a Japanese platform focused on diabetic screening. Their mutual objective is to deploy artificial intelligence for point-of-care screening of diabetic retinopathy, thereby facilitating rapid and exact diagnoses. This strategic partnership empowers primary care physicians to conduct screenings for diabetic retinopathy directly within their own clinical settings, aiming to mitigate instances of non-adherence to screening protocols and bridge existing gaps in care by providing prompt, reliable evaluations at the immediate point of service.

Diabetic Retinopathy Market Major Participants And Competitive Dynamics

Major companies operating in the diabetic retinopathy market are Pfizer Inc., F-Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Regeneron Pharmaceuticals Inc., Allergan plc., Genentech Inc., Santen Pharmaceutical Co Ltd., Carl Zeiss Meditec AG, Lumenis Ltd., Optos Plc., Quantel Medical SAS, NIDEK Co Ltd., IRIDEX Corporation, Alimera Science Inc., Oxurion NV, EyePoint Pharmaceuticals, Opthea Limited, KalVista Pharmaceuticals Inc., Regenxbio Inc., Kodiak Sciences Inc., Oculis, Verseon International Corporation, Clearside Biomedical Inc.

Access The Complete Diabetic Retinopathy Market Report:

https://www.thebusinessresearchcompany.com/report/diabetic-retinopathy-global-market-report

Diabetic Retinopathy Market Regional Analysis And Leading Geography

North America was the largest region in the diabetic retinopathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic retinopathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model